Alkylating Agent

9 Drugs classified under this drug class

Alkylating Agent. Busulfan 60 mg / 10 ml.
VIALS (sol. for inject.): 1. Every 6 hrs. for
4 consec. days for total of 16 doses.
In comb. with other chemother. agents
and/or radiother. as cond. ther. prior to
hematopoietic progenitor cell transplant.
C/I: Hypersens.

Alkylating Agent. Calcium Folinate 10 mg/ml.
VIALS (sol. for inj.): 1 x 100 mg/10 ml, 200 mg/20 ml, 500 mg/50 ml, 1000 mg/100 ml.
I.V./I.M. only. If use I.V: No more than
160 mg/min, diluted with 0.9% sod.
chlor. sol. or 5% glucose sol. See lit.
To diminish the toxic. and counteract the
action of folic acid antagonists in
cytotoxic ther. As Leucovorin-Fluorouracil
chemotherapy comb. for cancer tmt.
C/I: Hypersens., pernicious anem., other
anem. due to B12 defic.

Alkylating Agent. Dacarbazine (as Citrate) 200, 500, 1000 mg/vial.
SINGLE DOSE VIALS (Pwdr. for sol. for
inject./infus.): 1, 10 x 200 mg; (Pwdr. for
soln for infus.): 1, 10 x 500 mg, 1,000 mg.
Malign. melanoma: (as single agent):
200-250 mg/m2 bdy surface area/day)
I.V. for 5 days every 3 wks. Alt: Shortterm
infus. (over 15-30 mins). Also
possible: I.V. 850 mg/m2 on day 1, then
once every 3 wks. Hodgkin’s dis: 375
mg/m2 I.V. every 15 days in comb. with
doxorubicin, bleomycin and
vinblastine. See lit.
Malign. melanoma, Hodgkin’s dis.
C/I: Hypersens., pregn., lact., leucopen.,
and/or thrombocytopen., severe liver/
kidney dis.

Alkylating Agent. Dacarbazine 200 mg/vial.
VIALS (pwdr. for reconstit.): 1 x 200 mg +
19.7 ml water. I.V. inject.,/infus.
Monother: 4-5 day cycles of 150-250
mg/m² bdy surface/day. May repeat
every 21 days. Alt. tmt: 2.0-4.5 mg/kg/
day for 1-10 days. Can repeat every 28 days. Inject over ±1 min/infus. over
15-30 mins. If necess. may be given I.A.
Comb. chemother: 4-5 day cycles of
100 mg/m²/day with 21 day intervals
start. from last day tmt.
Metastat. malign. melanoma, Hodgkin’s
dis. as 2nd line ther. when used in comb.
with other agents.
C/I: Hypersens., ren. insuffic., bone
marrow defic., pregn., lact.

Alkylating Agent. Bendamustine Hydrochloride 25 mg, 100 mg.
VIAL (pwdr. for concentrate. for sol. for infus.): 5x25, 100 mg. Monother. for chron. lymphoc. leuk.: 100 mg/m² bdy. surf. area bendamustine HCl on 1^st and 2^nd day; every 4 wks. up to 6 times.
Monother. for indolent non-Hodgkin's lymphoma. refract. to rituximab: 120 mg/m² bdy. surf. area bendamustine HCl on on 1^st and 2^nd day; every 3 wks. for at least 6 times.
Follic. non-Hodgkin’s lymphom.: Comb. with rituximab: The dose is 90 mg/m² bdy. surf. area Demustin I.V. on 1^st and 2^nd day plus 375 mg/m² rituximab on 1^st day; repetit. every 4 wks.
1^st-line tmt. of chron. lymphoc. leuk. (Binet stage B/C) in pts. for whom fludarabine comb. chemother. is not appropr..
Indolent non-Hodgkin's lymphoma. as monother. in pts., who have progres. during or within 6 mnths. follow. tmt. with rituximab or a rituximab contain. regimen.
Follicular non-Hodgkin’s lymphom. as 1^st line tmt. in comb. with rituximab.
C/I: Hypersens. Lact. Sev. hep. impair. (serum bilirub. > 3.0 mg/dl). Jaundice. Sev. bone marrow suppres. and severe blood count alterat. (leukocyte and/or platelet values dropped to < 3,000/μl or < 75,000/μl, respectively). Major surg. less than 30 days before start of tmt. Infec., espec. involv. leukocytopenia. Yellow fever vaccin.

Alkylating Agent. Cyclophosphamide 500 mg, 1 g.
VIALS (pwdr. for reconst.): 1 x 25 ml (500 mg), 50 ml (1g). See lit.
Malign. lymphoma, Hodgkin’s dis.,
lymphocyt. lymphoma, mixed cell type
lymphoma, Burkitt’s lymphoma, multiple
myeloma, leukem., mycos. fungoides,
neuroblastoma, ovary adenocarcinoma,
retinoblastoma, breast carcinoma, SLE.
C/I: Hypersens., impair. bone marrow
funct., pregn., lact.